Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 13/20 | 1.00 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.43 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.43 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.43 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19701896 | 0.84 | PIK3CD (1.00) | PIK3CDCYP3A4CYP2C9TSHRCYP2C19 | |
| SCHEMBL19711140 | 0.84 | PIK3CD (1.00) | PIK3CDCYP3A4CYP2C9TSHRCYP2C19 | |
| SCHEMBL19710599 | 0.83 | PIK3CD (0.70) | PIK3CDPLA2G7SMN1; SMN2CYP3A4CYP2C9 | |
| SCHEMBL19710601 | 0.80 | PIK3CD (0.66) | PIK3CDPLA2G7SMN1; SMN2CYP3A4CYP2C9 | |
| SCHEMBL26239989 | 0.78 | PIK3CD (0.63) | PIK3CDPLA2G7SMN1; SMN2CYP3A4TSHR | |
| SCHEMBL19701904 | 0.77 | PIK3CD (1.00) | PIK3CDCHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL3889887 | 0.76 | PIK3CD (0.60) | PIK3CDPLA2G7SMN1; SMN2 | |
| SCHEMBL19701902 | 0.76 | PIK3CD (1.00) | PIK3CDCHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL19701907 | 0.73 | PIK3CD (1.00) | PIK3CD | |
| SCHEMBL19701903 | 0.72 | PIK3CD (1.00) | PIK3CDCYP3A4CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170355707-A1 | BICYCLIC HETEROARYL AMINE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2017-12-14 | — | — | US | disclosed |
| US-20170355707-A1 | BICYCLIC HETEROARYL AMINE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2017-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355707-A1 | BICYCLIC HETEROARYL AMINE COMPOUNDS | PIK3R3, JAK2, JAK3 | PIK3CD 14/4885PLA2G7 2152/4885SMN1; SMN2 4355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.